Canada markets closed

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.30+0.06 (+0.65%)
At close: 04:00PM EDT
8.90 -0.40 (-4.30%)
After hours: 06:13PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close9.24
Open9.16
Bid9.25 x 1100
Ask9.99 x 800
Day's Range8.82 - 9.40
52 Week Range2.60 - 10.28
Volume400,247
Avg. Volume892,587
Market Cap992.756M
Beta (5Y Monthly)-0.49
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    BELLUS Health to Participate in the Jefferies Healthcare Conference

    LAVAL, Quebec, June 01, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY from June 8-10, 202

  • Business Wire

    BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights

    LAVAL, Quebec, May 11, 2022--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today reported its financial and operating results for the first quarter ending March 31, 2022.

  • Business Wire

    BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

    LAVAL, Quebec, May 02, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American Thoracic Society (ATS) 2022 International Conference, being held in San